poisar

Stocks · News reference

Edesa Biotech Granted Orphan Drug Designation for Paridiprubart by European Commission

Fiscal.ai

Edesa Biotech announced that the European Commission has granted orphan drug designation to its investigational drug, paridiprubart, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading